INNA
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
13/01/2024
Voltar para busca
Dado oficial do USPTO
PHYTOMAB
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
37
Atualização mais recente
13/01/2024
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 42
Data de depósito
06/04/2021
Data de registro
09/08/2022
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
09/08/2022
Última transação
09/08/2022
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
03
Localização do titular
KR
Examinador
WOLFE, YOUNG J
Unidade examinadora
N40
Localização atual
TMO LAW OFFICE 122
Descrição da marca
The mark consists of the word "PHYTOMAB" colored blue. The figures of split leaf consist of right upper part gradated green to light green and left lower part gradated blue to light blue. The color white appears along the line of leaf veins.
Titulares e representantes
Titulares
PHYTOMAB CO., LTD.
Representantes
Kisuk Lee Harness, Dickey & Pierce, PLC
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Medicines for the treatment of canceranticancer medicines; biological preparations for medicalpharmaceutical and veterinary purposesbiological preparations for treatment of cancer; proteins for medicalpharmaceutical and veterinary purposesprotein arrays for medical diagnosis purposes; biological vectors for medicalpharmaceutical and veterinary purposesviral vectors for treatment of cancer; preparations of transformation microorganisms for medicalpharmaceutical and veterinary purposesfor the treatment of cancer; preparations of microorganisms for medicalpharmaceutical and veterinary purposes used for enhancing biomolecule production for treating cancer; preparations of gene recombination for medicalpharmaceutical and veterinary purposes used for biomolecule production for treating cancer; recombinant cells for medicalpharmaceutical and veterinary purposes; cell lines for medicalpharmaceutical and veterinary purposes; medicalpharmaceutical and veterinary preparations for the treatment of cells; stem cells for medicalpharmaceutical and veterinary purposes; vaccines for medicalpharmaceutical and veterinary purposes; antibiotics for medicalpharmaceutical and veterinary purposes; anti-cancer preparations for medicalpharmaceutical and veterinary purposes; nucleic acid sequences for medicalpharmaceutical and veterinary purposes; biopharmaceuticals for treatment of hepatitis; biopharmaceuticals for the treatment of cancer; biopharmaceuticals for the treatment of auto-immune diseases
Classe 42
pharmaceutical research and development; chemistry serviceschemical analysis; synthetic biology servicesresearch and analysis in the field of synthetic biology; stem cells biology servicesresearch and analysis in the field of stem cell biology; Stem cell research services; drug discovery services using plant cells; drug discovery services using stem cells; development services of new pharmaceutical products; laboratory research services relating to pharmaceuticals; testing of pharmaceuticals; medical research; biotechnological research; biological research; chemical research; research and development services relating to genetic testing; research and development services relating to medicalpharmacological and veterinary science; laboratory research in the field of pharmaceuticalsbiologybiochemistry and chemistry; research and development services in the field of microorganisms and cells technology; research services in the field of chemistrybiochemistryenzymologybiologycell biology and biotechnology
Publicações
Histórico de despachos e eventos da marca no USPTO.
37 publicações encontradas
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
03/01/2024
NREP
NEW REPRESENTATIVE AT IB RECEIVED
09/06/2023
NURC
NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
06/06/2023
LIME
LIMITATION FROM THE IB EXAMINED AND ENTERED
03/05/2023
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
03/05/2023
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
06/02/2023
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
12/12/2022
FICS
FINAL DISPOSITION NOTICE SENT TO IB
18/11/2022
FIMP
FINAL DISPOSITION PROCESSED
18/11/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
09/11/2022
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
09/08/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
09/08/2022
GPNX
NOTIFICATION PROCESSED BY IB
24/05/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
24/05/2022
PUBO
PUBLISHED FOR OPPOSITION
24/05/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
04/05/2022
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
04/05/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/05/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
16/04/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/04/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/04/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
06/04/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
06/04/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
06/04/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
06/04/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
06/04/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/04/2022
RFNT
REFUSAL PROCESSED BY IB
15/01/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
27/12/2021
RFRR
REFUSAL PROCESSED BY MPU
27/12/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
30/11/2021
CNRT
NON-FINAL ACTION WRITTEN
29/11/2021
DOCK
ASSIGNED TO EXAMINER
22/11/2021
MAFR
APPLICATION FILING RECEIPT MAILED
26/06/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
22/06/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
17/06/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace PHYTOMAB ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.